<DOC>
	<DOCNO>NCT00929344</DOCNO>
	<brief_summary>A 12-week , double-blind , placebo-controlled parallel group study conduct 150 outpatient alcohol dependence , random assignment pregabalin 300 mg/d , duloxetine 40 mg/d , placebo conjunction manual-guided behavioral counsel follow-up visit 1 week 3 month post-treatment .</brief_summary>
	<brief_title>Duloxetine Versus Pregabalin Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Males females 18 year age Meets DSMIV criterion current alcohol dependence drinking average ≥21 drink weekly male , ≥14 female , Seeking researchbased outpatient treatment alcohol problem Willing attend 12 weekly study visit 2 followup visit Have normal bilirubin , ALT , AST , GGT value 3x ULN , evidence hepatic insufficiency Active suicidal ideation Medical disorder increase potential risk interfere study participation Sexually active female subject childbearing potential pregnant , nursing refuse use reliable method birth control Males refuse use reliable method birth control Meets DSMIV criterion current major AXIS I disorder alcohol nicotine dependence . Inability understand and/or comply provision protocol consent form Treatment antidepressant medication two week , fluoxetine month , prior randomization Ongoing treatment disulfiram ( Antabuse ) , naltrexone ( ReVia ) , acamprosate ( Campral ) medication may affect study outcome , e.g. , anticonvulsant drug act serotonin brain Ongoing treatment drug may increase potential risk ( Actos ) ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alcohol</keyword>
	<keyword>Alcohol treatment</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Alcohol Dependence</keyword>
</DOC>